Advertisement

Topics

Latest "BioTech Capital Limited" News Stories

00:31 EDT 21st August 2018 | BioPortfolio

Here are the most relevant search results for "BioTech Capital Limited" found in our extensive news archives from over 250 global news sources.

More Information about BioTech Capital Limited on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about BioTech Capital Limited for you to read. Along with our medical data and news we also list BioTech Capital Limited Clinical Trials, which are updated daily. BioPortfolio also has a large database of BioTech Capital Limited Companies for you to search.

Showing "BioTech Capital Limited" News Articles 1–25 of 10,000+

Relevant

The Top 10 Biotech Companies in Copenhagen

The capital of one of the happiest countries in the world, Copenhagen has become a big hub for biotech in Europe. Here are some of the best biotech companies brewing in the Danish capital. Following the example of Novo Nordisk, ... The post The Top 10 Biotech Companies in Copenhagen appeared first on Labiotech.eu.


The 10 Biotech Venture Capital Firms in Europe to Watch in 2018

Who’s funding the biotech industry in Europe? I’ve gathered a list of some of the most active European biotech venture capital firms that will be setting the pace of the industry this year. Biotech can do great things, from curing ... This awesome article The 10 Biotech Venture Capital Firms in Europe to Watch in 2018 appeared first on Labiotech.eu. Be kind and don't copy it without as...

Oncolytics Biotech Announces Listing on Nasdaq Capital Market

Oncolytics Biotech (TSX:ONC) (NASDAQ:ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that its shares of common stock were approved for listing on the Nasdaq Capital Market. Oncolytics Biotech’s common stock will commence trading on the Nasdaq Capital Market today, June 1, 2018, under the symbol R...


China's I-Mab Raises $220 Million in C Round for Biotech Development

China's I-Mab Biopharma completed a $220 million Series C round led by Hony Capital. It was, according to the company, one of the largest C rounds ever for an innovative China biotech. I-Mab was formed in early 2017 when C-Bridge Capital and Tasly Pharma merged two China entities, Third Venture Biotech and Tasgen Bio, and invested $150 million in the consolidated company. At the time, I-Mab was sa...

eG Capital: Australian Biotech: A 2007 Perspective from Alison Coutts

In this exclusive interview, Fintan Walton talks to Alison Coutts, Executive Director at eG Capital in Sydney, Australia. Alison reviews some of the major changes she has observed in the biotech and pharmaceutical industry in Australia over the last 12 months, reflecting on the progress that many companies have made and the general maturation of the industry as a whole. She discusses the increasin...

AstraZeneca to spin out biotech company focused on autoimmune diseases

AstraZenica has announced that MedImmune, its biologics research and development arm, will spin out a new, independent biotech company named Viela Bio, which will focus on developing medicines for severe autoimmune diseases, according to a press release.The new company will start with three clinical and three preclinical potential new medicines — all molecules from MedImmune’s early-stage infl...

Aisling Capital: Investment Strategies and How to Revive Biotech

In this episode of PharmaTelevision News Review, Fintan Walton talks with Dennis Purcell at Aisling Capital. Filmed at Bio-Europe Spring 2010 in Barcelona, Spain, they discuss: • Dennis' history in the biotech sector • Key changes to biotech business models in the last 30 years • Aisling's investment strategy • How the company raised US $650M in January 2009, and how that fund is being ...

UK biotech riding on crest of VC funding wave - report

Venture capital funding for the UK biotech sector is robust following a solid start to the year, according to new data. According to a quarterly report from the BioIndustry Association and Informa, Venture Capital funding for the sector in Q2 was ...

Brii Bio Starts Operations with $260 Million to Bring Drugs to China

Brii Bio, a China-US startup, raised $260 million in initial capital to bring innovative drugs to China. So far, Brii has options on China rights to four biotech infectious disease assets from Vir of San Francisco. Brii, which plans to combine partnerships, R&D and digital/big data, will use WuXi AppTec and WuXi biologics for development of its projects, rather than building its own facilities...

MPM Capital: The Perfect Storm in Healthcare

In this interview, filmed at BioPharm in San Francisco, Dr Fintan Walton speaks with Vaughn Kailian, Managing Director at MPM Capital, one of the world's largest life science-dedicated venture investors. They discuss: • why 2009 has been a landmark year for the biotech industry • survival in the current financial crisis • healthcare reform and the politcs involved • how the best ideas wil...

Three Ways Venture Capital Firms Maximize Their Biotech Investments

ArticleThree major trends have emerged from the involvement of VC firms in early biotech development: early investment in biotech companies, leveraging big data, and mitigating regulatory risks.

The Biotech Growth Trust (BIOG) - Reasons to be optimistic

Edison Investment Research - Investment Companies - The Biotech Growth Trust: The Biotech Growth Trust (BIOG) is managed by Geoff Hsu and Richard Klemm of OrbiMed Capital. They aim to generate long-term capital growth from a diversified portfolio of global biotech equities. The managers are very optimistic on the industry outlook, citing a more benign political environment, a high level of innovat...

FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares - last conversion of Bracknor financing programme

FIT Biotech Oy Company release February 26, 2018 at 5:30 PM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares - last conversion of Bracknor financing programme Related to Convertible Note and Warrant Programmes established on September 26, 2016 between the FIT Biotech Oy ("Company") and Bracknor Investment ("Bracknor") the Company'...

#jobs #lifescience Process Engineer I (biotech)

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Process Engineer I (biotech) .CA-Elmira, The Process Engineer I will provide representation and leadership for the in the delivery of large capital projects for manufacturing-related facilities. This is … Continue reading → Cet article #jobs #lifescience Process En...

TVM Capital: Investment Strategies, Relationships with Big Pharma and Biotech Financing

In this episode of PharmaTelevision News Review, Fintan Walton talks with Dr Axel Polack, General Partner at TVM Capital. Filmed at BioBusiness 2010 in London, England, they discuss: • TVM’s investment strategy • Platform companies • The effects of the economic crisis • Milestones, exit strategies and the lack of an IPO market • Relationships with big Pharma • Financing in the biotec...

Mitra RxDx completes $40.8mm Series C

Mitra RxDx Inc. (Mitra Biotech; developing a cancer response prediction assay) raised $40.8mm through its Series C round from...

#jobs #lifescience Zenopa: Capital Equipment Technical Sales Specialist

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Zenopa: Capital Equipment Technical Sales Specialist . Base salary from £27,000-£35,000 based on experience, 25% bonus and company car or allowance: Zenopa: Suitable for a commercially minded scientist … Continue reading → Cet article #jobs #lifescience Zenopa: C...

Mitra RxDx brings in $27.4mm through Series B round

Mitra RxDx Inc. (Mitra Biotech) raised $27.4mm through its Series B round from new investors Sequoia India, Sands Capital Ven...

Meet the Experts: Discussion on Early-Stage Financing of Biotech Companies in Europe

Fintan Walton leads our panel of industry experts in an in-depth discussion about the early-stage financing of biotech companies in Europe. With viewpoints from both financial and biotech companies, our panellists provide a refreshing perspective on the current issues that face would-be CEOs, trying to secure seed capital in Europe's biotech start-up arena.

#news #biotech Alta raises $130M for its new biotech VC fund, missing its $200M goal

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Alta raises $130M for its new biotech VC fund, missing its $200M goal .Healthcare venture capital firm Alta Partners has launched a new fund focused on companies developing … Continue reading → Cet article #news #biotech Alta raises $130M for its new biotech VC fun...

VCs Are Pouring Billions into Biotech in 2018

While the focus has been on M&A activity, Venture Capital firms have been investing billions in Biotech companies in 2018.

Crowdsource Funding to Launch a Biotech: Is it as Crazy as it Sounds?

The typical way for a biotech to launch is for a scientist, often academia-based, to have come up with a discovery that shows commercial promise—sometimes rather far down the line. Venture capital (VC) firms are on the alert for this type of thing (and vice versa).

Maxim Group lowers price target for Matinas BioPharma, anticipating another capital raise in 2018

The analysts felt that at the current burn rate the biotech would need another capital raise in 2018, despite closing a US$7.1mln equity financing round in June

Paul Capital Partners: Growth Capital Providers for the Biotech Industry

In this interview, filmed during the recent BIO conference in San Diego, Fintan Walton speaks with Ken Macleod, partner in the well-known Paul Capital Partners, located in London. He tells how the company differs from traditional venture capitalist funds by providing funding based on royalty interests and revenue interests. Using these methods, Paul Capital is able to provide non-dilutive funding ...

RBC Capital belässt Morphosys auf 'Underperform' - Ziel 57 Euro

Das Analysehaus RBC Capital hat die Einstufung für Morphosys nach Jahreszahlen auf "Underperform" mit einem Kursziel von 57 Euro belassen. Die Kennziffern des Biotech-Unternehmens hätten den Konse...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks